Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 17,858 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 17,858 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $1.08, for a total value of $19,286.64. Following the sale, the director directly owned 2,890,128 shares of the company’s stock, valued at $3,121,338.24. This trade represents a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Luke Evnin also recently made the following trade(s):

• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total transaction of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.
• On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $33,858.27.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $12,883.86.

Werewolf Therapeutics Price Performance

NASDAQ HOWL traded up $0.01 during trading on Friday, reaching $1.10. 368,752 shares of the company traded hands, compared to its average volume of 481,383. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a market cap of $53.39 million, a price-to-earnings ratio of -0.68 and a beta of 0.74. The stock’s 50 day moving average price is $1.28 and its two-hundred day moving average price is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics during the second quarter worth about $28,000. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $48,000. Nuveen LLC bought a new position in Werewolf Therapeutics during the 1st quarter worth approximately $71,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the first quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics in the second quarter valued at approximately $92,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HOWL shares. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. JMP Securities cut their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Finally, Bank of America decreased their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.